Skip to main
  1. Stocks
  2. Regeneron Pharmaceuticals
  3. Forecast
REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals (REGN) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 40%
Buy 28%
Hold 32%
Sell 0%
Strong Sell 0%

Bulls say

Regeneron Pharmaceuticals is supported by a durable commercial base, led by Dupixent’s $6.54B global sales and Eylea HD’s record $699M U.S. quarter, which helped drive total revenue of $5.116B and non-GAAP EPS of $20.07, both well above expectations. Its outlook is strengthened by the first full quarter of profit share from the Sanofi alliance after the development balance was repaid, plus a $1B upfront to be recognized in 4Q26, alongside gross margin guidance rising to about 86% and share repurchases supporting earnings power. Beyond the core franchises, a broad pipeline in ophthalmology, immunology, oncology, and genetic medicine offers multiple shots on goal, while cash of about $18.9B leaves room to fund growth without sacrificing financial flexibility.

Bears say

Regeneron Pharmaceuticals is facing a negative outlook because its core Eylea franchise is exposed to accelerating biosimilar erosion, new biologic competition, patent risk, and slower-than-expected patient migration to Eylea HD, all of which could pressure revenue and market share. The company also faces moderating Dupixent growth as recent indication launches annualize, uncertainty around Dupixent’s life cycle, and the possibility that expansion into new indications or Libtayo and other pipeline programs may not offset mature-product headwinds. Despite a strong R&D engine and medium-term growth opportunities, near-term upside appears limited by clinical and regulatory setbacks, U.S. pricing pressure, and the risk that higher R&D investment in 2027 further compresses returns.

Regeneron Pharmaceuticals (REGN) has been analyzed by 25 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 28% recommend Buy, 32% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Regeneron Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Regeneron Pharmaceuticals (REGN) Analyst Forecast & Price Prediction

Get the latest Regeneron Pharmaceuticals (REGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Regeneron Pharmaceuticals (REGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Regeneron Pharmaceuticals (REGN) Forecast

Analysts have given Regeneron Pharmaceuticals (REGN) a Buy based on their latest research and market trends.

According to 25 analysts, Regeneron Pharmaceuticals (REGN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $909.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $909.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Regeneron Pharmaceuticals (REGN)


Regeneron Pharmaceuticals (REGN) Analyst Forecast & Price Prediction

Get the latest Regeneron Pharmaceuticals (REGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Regeneron Pharmaceuticals (REGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover REGN stock data and trends